Compare PAGS & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAGS | CDNA |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2017 | 2007 |
| Metric | PAGS | CDNA |
|---|---|---|
| Price | $8.92 | $66.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 7 |
| Target Price | $11.30 | ★ $58.83 |
| AVG Volume (30 Days) | ★ 2.4M | 1.0M |
| Earning Date | 11-11-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.13 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $6.82 | $30.36 |
| Revenue Next Year | $5.90 | $6.23 |
| P/E Ratio | ★ $7.74 | $30.04 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $8.42 | $13.95 |
| 52 Week High | $12.32 | $65.50 |
| Indicator | PAGS | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 78.88 |
| Support Level | $8.55 | $17.26 |
| Resistance Level | $9.42 | N/A |
| Average True Range (ATR) | 0.29 | 2.87 |
| MACD | -0.08 | 0.90 |
| Stochastic Oscillator | 24.63 | 99.39 |
PagSeguro Digital Ltd is a Brazilian-based company that acts as a provider of financial technology solutions focused on Micro-Merchants, Small Companies and Medium-Sized Companies (SMEs), in Brazil. The company provides a range of solutions and tools such as cash-in and cash-out options and provides access to working capital to help to manage its cash flow. It delivers an end-to-end digital ecosystem to address day-to-day financial needs, including receiving and spending funds and managing and growing businesses for clients. The company also offers the Free PagSeguro Digital Account delivering Cash-In Solutions, Online and In-Person Payment Tools, Online Payment Tools; and Web Check Outs offer tokenization, handling of shipping information, and others.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.